In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmas Urged To Take Committed Steps Along The IDN Pathway

Executive Summary

Integrated Delivery Networks can have a major influence on the drug classes prescribed by physicians affiliated with their network. IMS urges pharma companies to approach these increasingly important partners in health care delivery with strategies that are significantly different than those they've used in the past.

You may also be interested in...



UK MHRA In The Spotlight As Cumberlege Review Puts Medtech Safety At The Top Of Health Agenda

The findings of the Cumberlege Review into how safety issues for three medical product groups were handled will shape debate on the UK’s new devices legislation, now going through parliament. The MHRA’s devices regulatory activity also comes in for scrutiny.

UK Medtechs Fear That Pre-COVID-19 Activity May Be Over A Year Away

Top of the agenda for the medtech industry globally is when the “new normal” will return. In the UK, the expectations are that post-COVID-19 health care activity will increase gradually, but it is possible that the National Health Service will not reach its pre-coronavirus capacities until late in 2021, “if at all.”

UK NHS Urged To 'Bottle COVID-19 Spirit' For Future Health System Change

Residual resistance to digital health care solutions in the UK NHS disappeared “almost overnight” when COVID-19 compelled the rapid adoption of new tools to meet the surge in demand and cope with supply challenges.

Topics

UsernamePublicRestriction

Register

LL1128165

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel